Epilepsy News

BOSTON — Laser interstitial thermal therapy may offer seizure freedom to select patients, particularly those with drug-resistant temporal lobe epilepsy, according to a poster at the American Academy of Neurology annual meeting.

BOSTON — Implantation of GABAergic interneuron cells in two patients with drug-resistant focal epilepsy resulted in significant seizure reduction, according to preliminary data presented at the American Academy of Neurology annual meeting.

In adults with drug-refractory focal epilepsy, treatment with an implanted neurostimulation device was safe and associated with significant reduction in seizure frequency, according to a study published in JAMA Neurology.

Stoke Therapeutics Inc. announced the FDA will allow administration of a higher single dose of its investigational drug STK-001 in its ongoing phase 1/2a MONARCH study of children and adolescents with Dravet syndrome.

Medical technology company LivaNova has announced the launch of SenTiva Duo, an implantable pulse generator that provides vagus nerve stimulation therapy for patients with drug-resistant epilepsy.

Agoraphobic symptoms were common and associated with poor quality of life in adults with epilepsy, while generalized anxiety symptoms were not, according to a study published in Epilepsy Research.

A novel 3D video imaging tool has shown high potential for the use of real-time classification of epileptic seizures in hospitals, researchers reported in Scientific Reports.

An association between common antiepileptic drugs and incident Parkinson’s disease was found, researchers reported in JAMA Neurology.

Genetic-based screening tests among children with epilepsy may provide knowledge into the clinical characteristics of molecular diagnoses of rarer forms of the disorder, researchers found.

Fresenius Kabi announced the immediate availability of lacosamide injection, an approved treatment option for partial-onset seizures in those aged 17 years and older, in the United States.